Chugai to divest Oxarol Injection to LTL Pharma in Japan

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) says it will transfer the business of the secondary hyperparathyroidism drug Oxarol for Injection (maxacalcitol) to LTL Pharma in Japan.

Chugai, which is majority owned by Swiss pharma giant Roche (ROG: SIX), currently holds the manufacturing and marketing authorization in Japan and has been marketing Oxarol for Injection and providing information in Japan since 2000.

In consideration of the maturity of its product lifecycle, Chugai has considered its future domestic marketing. As a result of discussions between Chugai and LTL Pharma, it was agreed that Chugai would transfer the assets relating to Oxarol for Injection in Japan, including manufacturing and marketing authorization, to LTL Pharma., and LTL Pharma would thereafter be responsible for sales and promotion of Oxarol for Injection. LTL Pharma has a mission to ensure the stable and continuous delivery of Long-life Medicines to patients, and will strive to preserve and update the safety and quality data of Oxarol for Injection.